MARKET

ADXN

ADXN

Addex Therapeutics Ltd
NASDAQ
7.62
-0.13
-1.68%
Opening 10:24 02/11 EST
OPEN
7.52
PREV CLOSE
7.75
HIGH
7.89
LOW
7.52
VOLUME
1.40K
TURNOVER
--
52 WEEK HIGH
12.05
52 WEEK LOW
6.51
MARKET CAP
9.39M
P/E (TTM)
-0.9098
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at ADXN last week (0202-0206)?
Weekly Report · 2d ago
Addex publishes negative allosteric modulators data in Molecular Psychiatry
TipRanks · 02/03 10:40
Addex Therapeutics präsentiert präklinische Daten zu neuem Ansatz bei Angststörungen
Reuters · 02/03 06:00
Addex Therapeutics Unveils mGlu7 Modulator as Potential Game-Changer for Anxiety and PTSD Treatment
Reuters · 02/03 06:00
Weekly Report: what happened at ADXN last week (0126-0130)?
Weekly Report · 02/02 10:33
Weekly Report: what happened at ADXN last week (0119-0123)?
Weekly Report · 01/26 10:33
Weekly Report: what happened at ADXN last week (0112-0116)?
Weekly Report · 01/19 10:40
Addex Therapeutics Ltd – ADR trading resumes
TipRanks · 01/13 17:31
More
About ADXN
Addex Therapeutics Ltd is a Switzerland-based clinical-stage pharmaceutical company. The Company focuses on development and commercialization of orally available small molecule drugs known as allosteric modulators for neurological disorders. The Company’s clinical programs pipeline include dipraglurant (mGlu5 NAM), which is Phase 2a placebo-controlled clinical trial for Parkinson's disease levodopa-induced dyskinesia (PD-LID), and is being prepared to enter registration trials for PD-LID, and ADX71149 (mGlu2 positive allosteric modulator or PAM), which is being developed in collaboration by its partner Janssen Pharmaceuticals, Inc to treat schizophrenia and anxious depression. It also is advancing several preclinical programs, including GABABPAM for pain, overactive bladder and other disorders, mGlu7 NAM for post-traumatic stress disorder, mGlu2 NAM for mild neurocognitive disorders, mGlu4 PAM for Parkinson’s disease and mGlu3 PAM for neurodegenerative disorders.

Webull offers Addex Therapeutics Ltd - ADR stock information, including NASDAQ: ADXN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ADXN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ADXN stock methods without spending real money on the virtual paper trading platform.